Johnson & Johnson’s (J&J) anti-inflammatory Icotyde (icotrokinra) has secured FDA approval, marking the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis and signaling a potential shift in first-line systemic treatment options. The once-daily therapy is indicated for adults and adolescents aged 12 years and older who are candidates for systemic therapy or phototherapy. Unlike […]